Dr. Khasraw’s research interests include biomarker development and design of innovative clinical trials to improve outcomes for patients with primary and metastatic cancers of the central nervous systems. He is a Neuro-oncologist, professor of medicine and Deputy Director of the Center for Cancer Immunotherapy at Duke University, USA. He is interested in translating research into new therapies. At Duke, he is tasked with speeding up clinical research and translation for scientists across all departments and tumor sites.
Dr. Khasraw is leading several clinical and translational programs with significant laboratory collaborations and is the principal investigator on first-in-human Phase I immunotherapy clinical trials in solid tumors. He serves as an advisor and grant reviewer for several non-profits and patient advocacy groups. He is a Fellow of the Royal Australasian College of Physicians and an Elected Fellow of the Royal College of Physicians (UK) and an Honorary Professor at the University of Sydney (Australia).
Dr. Thomas’ focus is on the application of genomic technologies to the understanding and management of cancer. He is Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research, and a National Health & Medical Research Council (NHMRC) L3 Investigator. He is CEO of Omico, a non-profit company with a national precision medicine program for patients with advanced and early onset cancers, which he established in 2019. He is also Conjoint Professor, UNSW, Sydney.
Dr. Thomas is an internationally recognized leader in his field and is especially interested in precision oncology and clinical trials, somatic and germline cancer genomics, and sarcomas and cancer in young adults. He founded the Australasian Sarcoma Study Group, a national research organization, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. He leads the International Sarcoma Kindred Study, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.
Dr. de Ferris’ research focus is on healthcare transitions and increasing autonomy for children with chronic kidney disease as they move from childhood to adulthood. She is Professor, UNC School of Medicine, Dept. of Pediatrics and Director, UNC Transition and Self-Management Program. Her clinical practice is in pediatric nephrology.
Dr. de Ferris is also the Associate Director, Medical Student Research Program, UNC School of Medicine. Her transition work is internationally known and has helped to create systems that address crucial gaps to assure health so chronically ill children can become successful adults. She is the founder and Director of the UNC STARx self-management/transition program that provides education and intervention in an individualized, culturally, linguistically and age-appropriate fashion. She considers success with her patients as the best payment for her work.
Dr. Trimarchi’s research focuses on glomerular diseases, particularly in proteinuria and podocyturia, IgA nephropathy, focal and segmental glomerulosclerosis and Fabry disease, in the endothelium in renal replacement therapies. He is Head of the Division of Nephrology and Renal Transplantation at the Hospital Británico de Buenos Aires and a member of the Steering Committee of the International IgA Nephropathy Network. He is involved in many clinical research protocols related to glomerular diseases and chronic kidney diseases as member of the advisory board and steering committee, as KOL or national coordinator.
Dr. Trimarchi is Professor of Medicine of the Universidad Católica Argentina and Director of the Post Graduate Course of Internal Medicine of the Universidad de Buenos Aires School of Medicine at the Hospital Británico. He is a member of the ISN Continuing Medical Education Program Committee and an active member of the International Society of Nephrology and of the International Society of Transplantation. He has served as PI for sponsored clinical trials related to hypertension, IgA nephropathy, membranous nephropathy and focal and segmental glomerulosclerosis.
Graham gained his degree and PhD in Neuropharmacology from the University of Edinburgh Medical School. His more than 30 years of biopharmaceutical industry experience includes 10 years focusing on the discovery of novel compounds for the treatment of stroke and chronic pain (GSK, Pfizer, Servier) and 20 years in CNS clinical development in the biotech sector and with global CROs. Graham has worked on over 50 Phase I-IV clinical development programs including the planning and management of 13 Phase III programs with compounds that obtained NDA approval with the FDA. Most recently he held the position of VP, Clinical Development with the CNS focused biotech Travecta Therapeutics, and prior to that was VP, CNS Clinical Development with Syneos Health, providing scientific and strategic drug development expertise across a wide range of indications including dementia, movement disorders, stroke multiple sclerosis, mood disorders, acute & chronic pain and rare CNS diseases. Graham has been an invited speaker at several international conferences and has published 2 patents and over 25 scientific papers in major journals.
Dr. Wabnitz has extensive leadership and experience with a unique combination of clinical medicine, pharmacology, and industry drug development experience. He is Consultant Physician at Royal Adelaide Hospital (FRACP), Australia. He is a passionate expert in Phase I / First in Human clinical trials and drug development, pharmacology, chemistry and toxicology. He is qualified in regulatory submissions, HREC reviews/approvals, clinical trial design and execution, medical monitoring and extensive clinical trial networks within Australia, Asia, EU and the USA.
Dr. Wabnitz’s primary driving force is to bring quality therapies with appropriate risk/benefit to patients in most need, predominately oncology patients. He has significant experience in “hands-on” preclinical development (PK/TK/DDI/Metabolism/Toxicology), and has acted as Principal Investigator and Medical Monitor on numerous Phase I and II trials as well as being the Medical Director of an Australian Phase I unit. Dr. Wabnitz is an Advanced Training Specialist in Medical Oncology who has authored 22 peer-reviewed journal articles on biologicals, peptides, proteins, drug development and cancer / Medical Oncology research.
Dr. Kotwal is a clinical nephrologist at Prince of Wales Hospital in Sydney Australia, Program Head of the Renal and Metabolic Division at The George Institute for Global Health and a senior clinical lecturer at the University of NSW. She is the principal investigator for the Glomerular Disease Registry and Biobank in Sydney and the Global Kidney Patients Trial Network (GKPTN).
Her main interests include novel and pragmatic clinical trials and she is passionate about increasing clinical trial access for patients with kidney disease together with increasing personalized medicine capacity in Australia.
Professor Heerspink’s principal research interests include optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease in patients with diabetes with a specific focus on personalized medicine. He is Professor of Clinical Trials and Personalized Medicine; Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands; and visiting professor at the University of New South Wales in Sydney. He worked as a Postdoctoral Fellow at The George Institute for Global Health, Sydney, Australia, where he investigated the effects of blood pressure-lowering regimens on renal and cardiovascular outcomes in patients with chronic kidney disease.
Professor Heerspink leads and participates in clinical trials focused on renal and cardiovascular complications of Type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials. Based on his work at The George Institute, he was awarded a young investigator grant and subsequently in 2015 a consolidator investigator grant from the Dutch organization of scientific research and received in 2016 the Galien award for his research.
Professor Gallagher’s research interests include large scale clinical trials exploring ways to improve outcomes of kidney patients with a focus on acute kidney injury, long term treatment effects, and applying research evidence into practice. He is Associate Professor, Faculty of Medicine, UNSW, Sydney; Director of the Renal and Metabolic Division in The George Institute for Global Health; and a clinical nephrologist in the Renal Dept. at Concord Repatriation and General Hospital. He works extensively in the ANZ Society of Nephrology in renal guidelines and clinical policy.
Professor Gallagher is interested in the use of multi-disciplinary approaches and innovation to address major non-communicable health threats and works extensively in renal guidelines and clinical policy. At The George Institute for Global Health, he serves as Program Director, Acute Kidney Injury and Trials.
Professor Barratt’s research is focused on pathogenesis of IgA nephropathy and a range of areas across renal medicine including glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anaemia. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases and leads the Renal Research Group within the College of Life Sciences, University of Leicester. He also participates in other IgA nephrology initiatives such as the International IgA Nephropathy Network and in workgroups identifying endpoints for clinical trials such as the FDA and ASN Kidney Health Initiative.
Professor Barratt has been Principal Investigator for international randomized controlled clinical trials in IgA nephropathy and has attended both the FDA and EMA as an expert witness for new therapies in IgA nephropathy. He is an Editorial Board member for Kidney International and Clinical Journal of the American Society of Nephrology and sits on the Kidney Research UK Grants committee.
Dr. Jha’s research is focused on understanding the health and societal impact of kidney diseases globally and developing affordable, scalable and sustainable primary and secondary prevention tools. He is Executive Director, The George Institute for Global Health, India; President of the International Society of Nephrology; and Chair of Global Kidney Health, Faculty of Medicine, Imperial College of London. He serves on several international advisory boards, including membership of the WHO Expert Advisory Panel on Human Cell, Tissue and Organ Transplantation and the executive committee of the International Society of Nephrology.
Dr. Jha is recognized as a global expert on kidney disease, and focuses on emerging public health threats globally and in India. He has led research projects operating in more than 20 countries and works with a network of nephrologists to design and implement clinical studies for finding solution to the burden of kidney disease in India. He is particularly interested in using multi-disciplinary approaches and innovations to address the system level health and economic challenge posed to humanity by non-communicable diseases.
Dr. Liew’s research interests include glomerular diseases, peritoneal dialysis and diabetic kidney disease. He is a member of the Executive Committee of the ISN and chairs the ISN Oceania-Southeast Asia Regional Board. He serves as Senior Consultant Nephrologist and Director of The Kidney and Transplant Practice at Mount Elizabeth Novena Hospital, Singapore, and is a member of several KDIGO Guideline working groups.
Dr. Liew is responsible for the implementation of renal initiatives in Singapore and in the development of glomerular disease and peritoneal dialysis programs in Southeast Asia. In 2020, he became the only Singaporean and Southeast Asian to receive the John Mayer Award from the International Society for Peritoneal Dialysis, an award that honors individuals who have made significant contributions to the field of peritoneal dialysis. He chairs the Asian-Pacific Society of Nephrology Guideline working group on diabetic kidney disease and Dialysis Sub-group for the ISN Global Strategy for End-Stage Kidney Disease. He is also the national leader and global steering committee member for various multicentre clinical trials.
Dr. Pecoits-Filho’s research is focused on chronic kidney disease and he is currently a Visiting Researcher at The George Institute for Global Health, Sydney. He was a member of the Executive Committee of KDIGO and the International Society of Nephrology (ISN) and is currently the chair of the ISN Education Working Group, and part of the Core Group of ISN’s Advancing Clinical Trials Initiative. He is Senior Research Scientist at Arbor Research collaborative for Health; Professor of Medicine at the Pontifical Catholic University of Paraná in Brazil; and a practicing nephrologist.
Dr. Pecoits-Filhoh has played an active role in study design, implementation, coordination, event adjudication, data management and data monitoring safety for various trials. His participation in clinical trials includes as Principal Investigator, National Leader and Chair or member of steering committees. He has been featured in a series of ISN podcasts covering the diverse topics related to the field of nephrology and current issues that impact nephrologists around the world.
Dr. Wong’s research interest is in understanding the pathomechanism of kidney fibrosis and he has actively promoted the development of both clinical and pre-clinical research in delaying CKD progression in diabetic nephropathy, IgA nephropathy, and management of cardiovascular complications associated with CKD. He is a renal physician and Senior Staff Specialist at the Royal North Shore Hospital, Sydney; Senior clinical Lecturer of University of Sydney and University of NSW; and Senior Research Fellow, Renal & Metabolic Division for The George Institute and at the Kolling Institute.
Dr. Wong currently serves as the Head of the Renal Clinical trial unit at the RNSH and Co-Chair of the Research Group for the Chronic and Complex Medicine Network for Northern Sydney Lower Health District (NSLHD). He is the Deputy Chair of the Oceania South East Asia Regional Board, International Society of Nephrology (ISN) transitioning to Chair in 2021. As a member of the Working Group for Clinical Practice Guidelines for Diabetic Nephropathy for the APCN he has a focus on lower and middle income countries. He has been invited as Vice-Chair of the Program Committee for the Asia Pacific Society of Nephrology (ASPN) 2021 in Thailand.
Dr. Wheeler’s research interests are in chronic kidney disease complications, specifically those that increase cardiovascular disease burden and/or accelerate kidney failure progression. He is Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust and Professor of Kidney Medicine at University College London. He has participated in developing and running several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, and sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease. He has developed clinical practice guidelines for several organizations.
Dr. Wheeler is a Research Partner with The George Institute for Global Health and has developed clinical practice guidelines for several organizations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently Co-Chair. He is Clinical Lead for Division 2 of the North Thames Clinical Research Network and heads a team of eight Clinical Trials Nurses/Practitioners at the Centre for Nephrology, Royal Free Hospital in London. He is Past President of the UK Renal Association, past chair of the UK Renal Registry and currently National Institute for Health Research (NIHR) National Specialty Lead for Nephrology.
Professor Perkovic’s research is focused on clinical trials and epidemiology, including the prevention of progression and complications of kidney disease. He is Chair of the International Society of Nephrology Action for Clinical Trials group; Dean of Medicine and Scientia Professor at UNSW; and Professorial Fellow at The George Institute for Global Health. He also serves as Staff Specialist in Nephrology at the Royal North Shore Hospital.
Professor Perkovic has been involved in developing global guidelines for kidney disease, cardiovascular risk assessment and blood pressure management. He has made significant contributions with his work on diabetic nephropathy and studies of blood pressure lowering, lipid lowering and a range of other interventions for the prevention of kidney failure and cardiovascular outcomes in people with kidney disease.
Dr. Schwartzberg’s research interests include breast cancer, supportive care and developmental therapeutics. He is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno; and a founding Chief Medical Officer at OneOncology.. He was recently involved with genomic profiling of advanced cancer and is interested in visionary approaches to clinical research and oncology science. He divides his time between patients in the clinic and conducting clinical research trials and programmatic development.
A renowned expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is a member of the Board of Directors for the National Comprehensive Cancer Network and is the founding editor-in-chief of the journal Community Oncology. He is also the current editor-in-chief of the Practice Update Oncology website and serves on the editorial board for both the Journal of Supportive Oncology and the ASCO Post.
Dr. Boccia’s research interest is in cancers of the blood and blood-forming tissues as well as solid tumors, such as those seen in bladder cancer. He is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, and Clinical Associate Professor of Medicine at Georgetown University in Washington, DC. He also serves as the Chief Medical Officer for the International Oncology Network (ION). He conducts research in exploring the latest advances in colorectal cancer treatment and offers individualized care to patients with focus on multi-modal treatment regimens.
Dr. Boccia has studied and published cancer patients’ supportive care data on cytokine support for chemotherapy-induced anemia and leukopenia, and cytoprotective agents; specifically, amifostine (Ethyol) administration schedules designed to reduce side effects and improve safety. He is a member of numerous professional societies including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation.
Dr Jeremy Teoh’s research interests are in bladder and prostate cancer including urinary biomarkers for bladder cancer and androgen deprivation therapy for prostate cancer. He is Assistant Dean (External Affairs) and Assistant Professor of the Faculty of medicine, The Chinese University of Hong Kong. He is also Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong and Vice-Chair of the Young Fellows Chapter of the Hong Kong Academy of Medicine, and has been the Director of the Lions Kidney Educational Centre & Research Foundation since 2016.
Dr. Teoh developed a global consensus statement to standardize the en bloc resection approach and is studying the urinary biomarkers, tumour heterogeneity and molecular classification of bladder cancer. He has received numerous research grants with a total funding of more than HKD 30 million and has been serving as a member for several advisory boards for prostate cancer and bladder cancer. Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and believes that social media plays an important role in the modern era of medicine.
Dr. VanderWalde’s primary research is in melanoma, immunotherapy and targeted therapies based on immune markers and aberrations in cancer genetics. He is Vice President of Clinical Development, Caris Life Sciences, and Senior Medical Director, George Clinical. A thought leader in melanoma and clinical trial design and implementation, he has collaborated on advisory boards with many of the nation’s thought leaders and top experts in the field and previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing U.S. global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma.
As Former Director of Research at West Cancer Center and Research Institute, Dr. VanderWalde was responsible for managing the portfolio of all clinical trials. He is the former Director of Precision Oncology at OneOncology.
Dr. Loong’s clinical interests include sarcoma medical oncology, neuro-oncology, thoracic oncology and experimental therapeutics (Phase I clinical trials). He is based in Hong Kong and holds conjoint appointments of Clinical Assistant Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase I Clinical Trials Centre of The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. He has conducted over 50 oncology Phase I, II and III trials as either a Principal Investigator or Co-Investigator and is interested in actively helping to develop further capacity for oncology research within the APAC region.
Dr. Loong obtained his medical degree from The University of Hong Kong and completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a special focus on Experimental Therapeutics. He is a recipient of the European Cancer Congress Fellowship Grant (2013), the ASCO Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
Dr. Pluard’s research is focused on new targeted therapies of breast cancer. He is Medical Director, Saint Luke’s Cancer Institute and Koontz Center for Advanced Breast Cancer, Kansas City, MO. Previously, he was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University Siteman Cancer Center in St. Louis. He specializes in offering comprehensive care including advanced genomic and immunotherapy treatments to women with metastatic breast cancer and advises patients on participating in clinical trials for leading-edge treatments.
Dr. Pluard leads a team at St. Luke’s Cancer Institute focused on the comprehensive care of women with breast cancer where every woman’s tumor is genetically analyzed to understand what is driving their cancer. He emphasizes the importance of in-depth communication with patients taking a fully holistic approach to their treatment options. With his work at Saint Luke’s, Koontz Center and in clinical trials, Dr. Pluard strives to help define care for all women with advanced breast cancer.
Dr. Chandler specializes in medical oncology, hematology and blood cancers. He is Director of Research for Hematology Malignancies at West Cancer Center. Dr. Chandler was a co-leader in the efforts to gain FDA approval for the delivery of CAR-T therapy to cancer patients in 2019, paving the way for CAR-T therapies and treatments to be tested across the country. He is interested in research and immunology and committed to providing patients with access to early-stage clinical trials.
Dr. Kosiborod’s research has a strong focus on the intersection of diabetes and cardiovascular disease. He is Vice President of Research at Saint Luke’s Health System; Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute; and Professor of Medicine at the University of Missouri-Kansas City. He is an internationally recognized expert in diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
As a practicing clinician and researcher, Dr. Kosiborod seeks to establish a practical system of implementing adoption of new treatments that have been proven to be life saving into practice in a more timely manner. He continues to be involved in the leadership of numerous clinical trials and multi-center registries, and serve as the Principal Investigator of investigator-initiated, multi-center trials in diabetes and cardiovascular disease, most recently of SGLT2 inhibition.
Dr.Neal’s research interests include the environmental determinants of chronic disease and the potential for changes in the food supply to deliver large, cost-effective and equitable health gains. He was a founding member and currently serves as Executive Director, The George Institute for Global Health. He also serves as Professor of Medicine, UNSW Sydney, and Professor of Clinical Epidemiology at Imperial College London. He has expertise in the management of high blood pressure and diabetes and has played lead roles in multiple large-scale clinical trials. His work has been characterized by its focus on collaboration, quantitation, translation and impact.
Dr. Neal holds additional professorial appointments at Flinders University in South Australia, an honorary appointment at the University of Sydney and chairs the Australian Division of World Action on Salt and Health. He was identified by Thomson Reuters as one of ‘The World’s Most Influential Scientific Minds’, an acknowledgement provided to just 3000 researchers across all disciplines, worldwide. He has particular expertise in salt reduction but also a broader knowledge of food policy issues related to sugars, fats, portion size and food labelling. Dr. Neal has played lead roles in multiple large-scale clinical trials, most recently of SGLT2 inhibition.
Professor Schutte’s research focuses on the early detection, prevention and treatment of hypertension and cardiovascular disease in low resource settings. She has led several multidisciplinary projects in this field, including biomarker discovery, early vascular aging and polyomics. Serves as Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine in the Faculty of Medicine at the University of New South Wales, Sydney, Australia and Professorial Fellow at The George Institute for Global Health. She is involved in numerous international consortia, such as the Global Burden of Disease study, the NCD Risk Factor Collaboration, May Measurement Month initiative of the International Society of Hypertension and IDACO/IDCARS studies.
Professor Shutte has extensive experience in working in hypertension and cardiovascular disease within Africa, but also as part of global projects. In her previous role as the South African Research Chair in the Early Detection and Prevention of Cardiovascular Disease in Africa, hosted by the Hypertension in Africa Research Team (HART) at the North-West University and as Unit Director of Medical Research Council Extramural Unit for Hypertension and Cardiovascular Disease, her research focus was to identify early markers for the development of hypertension, and ultimately prevent cardiovascular disease in the black African population.
Professor Rodgers’ principal focus is on cardiovascular disease prevention, innovation and public-private partnerships, and in scaleable interventions to address major health risks. He is Professor of Global Health at The George Institute for Global Health and Chair of Clinical Epidemiology, Imperial College London. He was the principal author of the 2002 World Health Report, the main annual publication for WHO.
Since 2003 Professor Rodgers has led a public-private partnership developing an affordable four-in-one cardiovascular combination pill (‘polypill’), with a clinical trial program in economically developed and developing countries, funded by the Wellcome Trust, European Union and others. His current work aims to foster similar developments designed to be ‘fit for purpose’ in low income settings.
Dr. Huffman’s research focus is acute cardiovascular quality improvement, simplifying pharmacotherapy through fixed-dose combinations, programmatic implementation and evaluation for large-scale hypertension control, monitoring and improving the US and global food and medicine supplies, and achieving tobacco endgame. He is Director, Institute for Global Health – Center for Global Cardiovascular Health; Quentin D. Young Professor of Health Policy and Associate Professor at the Food Policy Division of The George Institute for Global Health; and Associate Professor of Preventive Medicine (Epidemiology) and Medicine (Cardiology) at Northwestern University.
Recognized as one of the brightest minds in both cardiovascular and food policy research worldwide, Dr. Huffman aims to improve global food and medicine supply and achieve tobacco endgame with a special focus on underserved populations. In 2019, Huffman was named an Emerging Leader in Health and Medicine Scholar by the National Academy of Medicine. He is a practicing cardiologist, researcher and teacher interested in global cardiovascular health epidemiology, clinical trials, implementation science, health systems and policy research and training. He has also served as Member, American Heart Association Institute for Precision Cardiovascular Medicine Task Force and as an expert reviewer for the Global Burden of Disease project.
Dr. Sundström’s research focuses on causes and consequences of hypertension. He is Professor of Epidemiology at Uppsala University; Conjoint Professor at The George Institute for Global Health, University of New South Wales; and a clinical specialist in the internal medicine and cardiology at Department of Cardiology, Uppsala University Hospital. He also heads the university’s Clinical Epidemiology research group.
Dr. Sundström is interested in using big data to create value for patients and populations and developing methods for risk estimation, treatment decisions and evaluation of treatment effects, risks and costs. In addition to creating data sources such as clinical trials and cohorts, he develops methods for emerging ones such as electronic health records and digital patient-generated data. He has made important contributions to the understanding of cardiovascular disease and its risk factors, with a focus on high blood pressure, and his work is cited in several international cardiovascular prevention and hypertension guidelines. At the George Institute for Global Health at Sydney University, he initiated a series of studies in the Blood Pressure Lowering Treatment Trialists’ Collaboration investigating optimal targeting of blood pressure-lowering treatment. He is currently contributing with unique research of the potential for “precision medicine”in cardiovascular disease.
Professor Chalmers’ research interests include large scale clinical trials and epidemiological studies related to hypertension, coronary heart disease and stroke, and diabetes and renal disease. He is Senior Director, Professorial Unit, The George Institute for Global Health and Professor of Medicine, UNSW Sydney, as well as Emeritus Professor of Medicine at Flinders University and at the University of Sydney.
At the George Institute, he serves as Principal Investigator on research grants and chair of steering committees for major studies.
Professor Chalmers’ studies on the treatment of high blood pressure for the prevention of heart attack and stroke have changed the way patients are treated throughout the world. They helped elucidate the brain mechanisms and neurotransmitters responsible for blood pressure control, and also demonstrated the benefits to stroke and Type II diabetes patients of lowering their blood pressure – whether it is considered clinically “high” or not. His contribution to medical science has been recognized through many awards, Honorary Doctoral degrees and extensive appointments on national and international boards and advisory committees. He was appointed a Companion in the Order of Australia (AC) in 1991 and an Officer in the National Order of Merit of France in 2010.
Research focused on clinical and epidemiological aspects of stroke, cardiovascular disease and aged care. Professor of Neurology and Epidemiology, Faculty of Medicine, UNSW Sydney, and in clinical practice at Royal Prince Alfred Hospital, Sydney. Executive Director of The George Institute for Global Health, China at Peking University Health Science Center, Beijing. Senior Investigator Fellow of the National Health and Medical Research Council of Australia. Past President of the Asia Pacific Stroke Organization and the Stroke Society of Australasia.
Dr. Delcourt’s research interests are stroke, health systems, clinical trials and epidemiology. She is Senior Research Fellow at The George Institute for Global Health and the Hunter Stroke Service in Newcastle, and Senior Clinical Lecturer at the University of Sydney. She has extensive experience in the design, management, conduct and reporting of clinical trials and as an adjudicator and medical reviewer for stroke and cardiovascular projects.
Dr. Delcourt is focused on improving stroke care, particularly in regional and rural Australia. She received more than $400,000.00 funding in 2019 from Australian government to reduce care gaps and improve outcomes for rural patients including use of telemedicine. She obtained her specialist medical qualification in Neurology from the University of Liege (Belgium) and additional qualifications in cerebrovascular medicine from the University of Dijon (France) and in neurophysiology from the University of Lille (France). She is an executive committee member of the Stroke Society of Australasia and the Australian Stroke Trial Network and holds a clinical appointment at the Royal Prince Alfred Hospital.
Dr. Jenkins’ research is focused on the clinical management of airways disease and patient reported outcomes in response to therapeutic interventions. She is Head of the Respiratory Group at The George Institute for Global Health; Senior Staff Specialist in Thoracic Medicine at Concord Hospital, Sydney; Clinical Professor and Head of Respiratory Discipline at University of Sydney; and Professor of Respiratory Medicine at UNSW Sydney. She also chairs the National Asthma Campaign and the Federal Government’s National Asthma Advisory Group.
Dr. Jenkins has been Principal Investigator and has led many investigator-initiated and competitively funded clinical trials in airways disease. She is an active clinician and has had major roles in advocacy and leadership for lung health in Australia, chairing many local and international guidelines and implementation initiatives to enhance resources, skills, capacity and clinical outcomes in airways disease. She is on the Board of the Lung Foundation Australia, and is a member of the Thoracic Society of Australia and New Zealand, the American Thoracic Society, European Respirator Society and the Asia-Pacific Society of Respirology.
Working in the Professorial Advisory Unit of The George Institute, Mark is also a Professor of Medical Statistics in the Faculty of Medicine, UNSW Sydney, Professor of Statistics and Epidemiology at the University of Oxford, where he is an Oxford Martin Senior Fellow and Adjunct Professor of Epidemiology at Johns Hopkins University.
He is the author of 400+ peer-reviewed publications and two text-books on statistical methods in medical research, one of which had its third edition published in January 2014. In the five year period from January 2009 to December 2013 he published 161 (>40% of his total) peer-reviewed publications, including seven in The Lancet, two in NEJM and one in JAMA. Three of his papers have over a thousand citations.
Mark has led four major international studies and directed the analytical research on three landmark collaborative studies, worldwide. His work on cardiovascular risk scores formed the basis of national guidelines in Scotland, and his recent work on kidney disease was used to produce new staging criteria for this disease. His total career grant awards are over $93 million from 39 successful applications.
He also has extensive experience in student teaching, postgraduate supervision and mentoring including 14 PhD and 19 MSc students successfully completed. He has given training workshops in Korea and Thailand, and has taught at least 25 other research training courses.
Mark served on the governing council of the Institute of Statisticians and the Royal Statistical Society (RSS) and is currently a fellow of the RSS, the European Society of Cardiology, the New York Academy of Medicine and the Royal Society of Medicine.
He has wide experience of development aid work in Africa and Asia, having undertaken 25 missions for aid agencies, such as the WHO. He has also assessed grants for six national medical research councils (including NHMRC) and served on the editorial boards of seven international journals.
Stephen Jan is Head of the Health Economics and Process Evaluation Program at the George Institute for Global Health and Professor, Faculty of Medicine, UNSW Sydney.
He is an Honorary Professor at the University of Sydney, a Director of the Sax Institute and an Associate at both the Menzies Centre for Health Policy and the Poche Centre for Indigenous Health. He is a current NHMRC Principal Research Fellow and has previously held posts at the London School of Hygiene and Tropical Medicine and the Centre for Health Economics Research and Evaluation (CHERE) in Sydney. Stephen has over 20 years of experience in health economics, has published over 200 scientific articles and authored two textbooks in health economics.
He has worked closely with various governments of different levels, both in Australia (Commonwealth and State) and overseas, with international agencies such as the WHO and industry. His areas of expertise are economic evaluation, health financing, health sector priority setting, Indigenous and global health issues and the economics of chronic disease.
Laurent is a senior biostatistician with 20 years of experience in health research. He is Director of the Statistics Division at the George Institute for Global Health and Associate Professor, Faculty of Medicine, UNSW Sydney.
He is responsible for providing statistical services to the George Institute and its collaborators in Australia and globally. He holds a Master of Science in Statistics and Computer Science and a Master of Research in Public Health (Biostatistics). He is an accredited statistician by the Statistical Society of Australia (AStat).
Professor John A Myburgh AO, is Professor of Intensive Care Medicine, UNSW Sydney; Director of the Division of Critical Care and Trauma at the George Institute for International Health and Senior Intensive Care Physician at the St George Hospital, Sydney. He holds honorary Professorial appointments at the University of Sydney and Monash University School of Public Health and Preventive Medicine.
He has an extensive research track record over 25 years and is regarded as a national and international expert in catecholamine neurophysiology and pharmacology, trials of clinical management of traumatic brain injury, fluid resuscitation and in the development and co-ordination of over 35 clinical trials in Intensive Care Medicine.
He is a Foundation Member and Past-Chairman of the Australian and New Zealand Intensive Care Society Clinical Trials Group. He was instrumental in the establishment of the Australian and New Zealand Intensive Care Research Centre at the Monash University School of Public Health and Preventive Medicine. In addition to his research profile, he has made a substantive contribution to education in Intensive Care Medicine, both at undergraduate and postgraduate levels over the last 25 years. He was instrumental in establishing the College of Intensive Care Medicine, serving as a Fellowship examiner for twelve years, on the Board for ten years and as the first elected President from 2010-2012.
In June 2014, he was made an Officer of the Order of Australia (AO) for distinguished service to medicine as an intensive care medical practitioner, educator and researcher, and as an international innovator in patient management.
Simon Finfer is a Professorial Fellow in the Critical Care and Trauma Division at The George Institute for Global Health. He is a practicing critical care physician with an appointment as a Senior Staff Specialist at Royal North Shore Hospital and Director of Intensive Care at the Sydney Adventist Hospital, the largest not-for-profit hospital in New South Wales.
Simon holds a Professor appointment at the University of New South Wales, and a Clinical Professor at the University of Sydney. He is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. He chairs the Council of the International Sepsis Forum, and is a member (Treasurer) of the Global Sepsis Alliance Executive. Simon is a member of the World Sepsis Day Steering Committee and recently co-chaired the 1st World Sepsis Congress, a two-day free online congress that attracted 14,000 registrants.
His postgraduate qualifications include Fellowships of the Royal Colleges of Physicians, the Royal College of Anaesthetists and the College of Intensive Care Medicine. He was elected to the ANZICS Honour Roll in 2011 and in 2012 he was awarded an honorary doctorate (Doctor of Medicine) by The Friedrich-Schiller University in Germany, an honour awarded once every 10 years. He is a Fellow of the Australian Academy of Health and Medical Sciences.
Simon’s major research interest is the design and conduct of large scale randomized controlled trials in critical care. Simon is active in forging major international research collaborations that have conducted large scale clinical trials and epidemiological research to improve the treatment of critically ill and injured patients. He has published over 150 peer reviewed papers, many in the most prestigious journal in the world. He is frequently invited to lecture at major international conferences.
Simon is an Editor of The Oxford Textbook of Critical Care (2nd Ed.), the Critical Care Section Editor for The Oxford Textbook of Medicine (6th Ed.), and was a guest editor for The New England Journal of Medicine from 2012 – 2014.
Professor Hunter is a rheumatology clinician-researcher whose main research focus is clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at the University of Sydney and Royal North Shore Hospital. He is ranked as the leading expert in the world on osteoarthritis on expertscape.com and is the section editor for UpToDate osteoarthritis. He holds a medical degree and Master of Sports Medicine from the University of New South Wales, a fellowship in Rheumatology at the Royal Australian College of Physicians and earned a Masters of Medical Science (Clinical Epidemiology) from the University of Newcastle and received his Ph.D. from the University of Sydney in 2001. He is an editor for leading international journals in his field, has authored books on osteoarthritis and has over 500 publications in peer-reviewed journals.